DDInter255 DDInter574
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Multiple Sclerosis (MS) is a chronic, debilitating neurological disease that can lead to profound cognitive and physical symptoms, severely affecting quality of life. It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS. Diroximel fumarate is a new drug from the fumarate class formulated to treat various relapsing forms of MS. This drug is bioequivalent to [Dimethyl fumarate][A187544,L9626](initially manufactured in 2013), but is less likely to cause gastrointestinal side effects, owing to its unique chemical structure. Diroximel fumarate was formulated by Alkermes in collaboration with Biogen, and was approved by the FDA in October 2019 and by the EMA in November 2021.
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Busulfan {u} (Compound) causes {v} (Side Effect) Headache
Headache {u} (Side Effect) is caused by {v} (Compound) Bexarotene
Bexarotene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is palliated by {v} (Compound) Methylprednisolone
Methylprednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Busulfan {u} (Compound) causes {v} (Side Effect) Blood uric acid increased
Blood uric acid increased {u} (Side Effect) is caused by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Diroximel fumarate
Busulfan {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Fingolimod
Fingolimod {u} may lead to a major life threatening interaction when taken with {v} Diroximel fumarate
Busulfan {u} (Compound) treats {v} (Disease) hematologic cancer
hematologic cancer {u} (Disease) is treated by {v} (Compound) Cladribine
Cladribine {u} may lead to a major life threatening interaction when taken with {v} Diroximel fumarate
Busulfan {u} (Compound) upregulates {v} (Gene) NOTCH1
NOTCH1 {u} (Gene) is upregulated by {v} (Compound) Trifluridine
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Busulfan {u} (Compound) downregulates {v} (Gene) CCND3
CCND3 {u} (Gene) is upregulated by {v} (Compound) Trifluridine
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Busulfan {u} (Compound) downregulates {v} (Gene) CCNB1
CCNB1 {u} (Gene) is downregulated by {v} (Compound) Trifluridine
Trifluridine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diroximel fumarate
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Bexarotene (Compound) and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Bexarotene (Compound) and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Busulfan (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Bexarotene (Compound) and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is palliated by Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Busulfan (Compound) causes Blood uric acid increased (Side Effect) and Blood uric acid increased (Side Effect) is caused by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Diroximel fumarate
Busulfan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fingolimod (Compound) and Fingolimod may lead to a major life threatening interaction when taken with Diroximel fumarate
Busulfan (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cladribine (Compound) and Cladribine may lead to a major life threatening interaction when taken with Diroximel fumarate
Busulfan (Compound) upregulates NOTCH1 (Gene) and NOTCH1 (Gene) is upregulated by Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Busulfan (Compound) downregulates CCND3 (Gene) and CCND3 (Gene) is upregulated by Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate
Busulfan (Compound) downregulates CCNB1 (Gene) and CCNB1 (Gene) is downregulated by Trifluridine (Compound) and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate